Alle Storys
Folgen
Keine Story von STMicroelectronics mehr verpassen.

STMicroelectronics

STMicroelectronics and Veredus Laboratories Team to Diagnose Avian Flu Using Rapid-Detection Point-of-Need Lab-on-Chip

Geneva and Singapore (ots/PRNewswire)

STMicroelectronics (NYSE:
STM) and Veredus Laboratories today announced that they are
developing a fast, point-of-need diagnostic capability that will
enable health practitioners to quickly detect strains of Avian Flu
and other influenza viruses. The diagnostic capability, which uses
reliable and inexpensive equipment, produces results within
approximately one hour of testing.
Using STMicroelectronics' well-characterized In-Check (TM)
platform, Veredus is developing an application to specifically
identify whether a patient is infected with the Avian Flu (H5N1) or a
subtype of Influenza A or B in a single test, instead of requiring
many tests, as needed currently. To be available in time for the next
flu season, the single-test application will be a substantial
breakthrough in enabling rapid identification of the infectious agent
to limit the spread of the disease and speed patients' treatment.
The diagnostic effort is being built on STMicroelectronics'
In-Check platform, a complete laboratory on a chip. The platform
allows users to accurately and reliably perform the complex
processing and analysis of a minute sample on a single disposable
chip, dramatically reducing the time and complexity of the
instrumentation needed. In addition, this self-contained lab-on-chip
approach reduces the risk of cross-contamination inherent in
conventional analysis methods. Results are detected by a dedicated
portable reader using optical signal acquisition and processed by
ST's specialized bioinformatics software, which can be installed on
any PC.
"The World Health Organization recently identified rapid detection
as the first requirement in fighting Avian flu, and ST's leading-edge
semiconductor expertise--combined with Veredus' expertise in Avian
Flu detection--will enable new possibilities for effective timely
detection and treatment so that early containment of the infection
will be possible," said Anton Hofmeister, Group Vice-President and
General Manager for ST's Microfluidic Division. "We are convinced
that affordable, user-friendly, and portable devices like In-Check
will make a critical difference in a growing number of diagnostic
applications."
"In light of the risk of a worldwide flu pandemic, and to limit
its potential global impact, we aim to provide health-care
professionals with the capability to quickly differentiate Avian Flu
or severe flu strains from milder strains by their subtypes," added
Dr. Rosemary Tan, CEO of Veredus. "In-Check is ideally suited to
serve as a platform on which to build Veredus' unique infectious
disease panels. This combination will enable rapid diagnosis and the
delivery of appropriate treatments for patients in the shortest time
possible. We are actively developing chips to detect Dengue, Malaria,
West Nile, Yellow Fever, Typhoid Fever, Japanese Encephalitis, and
other diseases and anticipate that our products will greatly improve
treatment choices."
Based on the encouraging results seen so far and following
extensive testing and validation, the Veredus application, running on
ST's In-Check platform, is expected to be commercially available to
health care providers in the fall of this year.
About STMicroelectronics
STMicroelectronics is a global leader in developing and delivering
semiconductor solutions across the spectrum of microelectronics
applications. An unrivalled combination of silicon and system
expertise, manufacturing strength, Intellectual Property (IP)
portfolio and strategic partners positions the Company at the
forefront of System-on-Chip (SoC) technology and its products play a
key role in enabling today's convergence markets. The Company's
shares are traded on the New York Stock Exchange, on Euronext Paris
and on the Milan Stock Exchange. In 2004, the Company's net revenues
were US$8.76 billion and net earnings were US$601 million. Further
information on  ST can be found at www.st.com.
About Veredus Laboratories Pte Ltd
Founded in 2003, Veredus Laboratories Pte Ltd is a privately held,
medical diagnostics company engaged in the development,
commercialization and manufacture of diagnostic assays for diseases.
As a successful enabler for innovative technologies, products and
services, Veredus is the partner of choice for academic and
increasingly industrial research in Life Sciences, Diagnostics and
Pharma. For more information, please visit www.vereduslabs.com.
Technical Note:
All of In-Check's core biochemical functionality is enabled by,
and on board, a Silicon chip which has been processed using standard
silicon-chip manufacturing. As a result, the In-Check Lab-on-Chip
benefits from the enormous economies of scale that have been realized
by the semiconductor industry.
To facilitate handling, the In-Check lab-on-chip is a mounted on a
small laboratory-slide-sized piece of plastic. This miniature
lab-on-chip contains its own, on-chip PCR (polymerase chain reaction)
reactor that starts with a small sample containing a few DNA strands.
The PCR precisely cycles the temperature to alternately separate and
replicate the few DNA strands into hundreds of thousands or millions
of identical strands. This on-chip multiplication of a small sample
gives In-Check substantial time and cost advantages over existing
approaches, which often need to start with a much larger sample that
can be more expensive to acquire and extract and requires processing
at remote laboratories using expensive, stationary equipment.
(TM) In-Check is a trademark of STMicroelectronics
    For further information, please contact:
    For Veredus Laboratories Pte
    Dr Rosemary Tan
    CEO, Veredus Laboratories Pte Ltd
    Mobile: +65-9619-9690
    Email:  rosemary@vereduslabs.com
    For STMicroelectronics
    Press contacts
    Burson-Marsteller
    Sandrine Romano                    Jonathan Dinkeldein
    Burson-Marsteller Paris            Burson-Marsteller London
    Tel: +33-1-41-86-76-77             Tel: +44-207-300-6150
    Email:  sandrine_romano@fr.bm.com   Email:  jonathan_dinkeledein@uk.bm.com

Contact:

For Veredus Laboratories Pte, Dr Rosemary Tan, CEO, Veredus
Laboratories Pte Ltd, Mobile: +65-9619-9690, Email:
rosemary@vereduslabs.com For STMicroelectronics Press contacts
Burson-Marsteller, Sandrine Romano, Burson-Marsteller Paris, Tel:
+33-1-41-86-76-77, Email: sandrine_romano@fr.bm.com; Jonathan
Dinkeldein, Burson-Marsteller London, Tel: +44-207-300-6150, Email:
jonathan_dinkeledein@uk.bm.com

Weitere Storys: STMicroelectronics
Weitere Storys: STMicroelectronics
  • 25.10.2005 – 23:51

    STMicroelectronics Reports 2005 Third Quarter and Nine Month Revenues and Earnings

    Geneva, Switzerland (ots/PRNewswire) - - All figures in US Dollars $ STMicroelectronics (NYSE: STM) reported financial results for the third quarter and nine months ended October 1, 2005. Revenues, Gross Profit, and Margin Review Net revenues for the third quarter were $2,247 million, up 3.9% sequentially from the $2,162 million reported in the prior ...

  • 17.10.2005 – 10:07

    STMicroelectronics Launches its 'Greater China' Region and Appoints Corporate Vice President

    Geneva, Switzerland (ots/PRNewswire) - STMicroelectronics (NYSE: STM) today announced the creation of its new 'Greater China' region, covering the Company's operations in China, Hong Kong, and Taiwan. ST also announced the appointment of Bob Krysiak as Corporate Vice President and General Manager of the new entity. Today, customers in the Asia Pacific region ...